Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2007;11(5):164.
doi: 10.1186/cc6090.

Activated protein C: cost-effective or costly?

Savtaj Singh Brar, Braden J Manns
Editorial

Activated protein C: cost-effective or costly?

Savtaj Singh Brar et al. Crit Care. 2007.

Abstract

The authors offer a commentary on the study by Dhainaut et al. on the cost-effectiveness of activated protein C in severe sepsis. Using data from "real world" conditions, the results of this economic evaluation are consistent with previous analyses, and highlight the need for "real world" investigations of new health technologies in critical care.

PubMed Disclaimer

Comment on

Similar articles

See all similar articles

Cited by

References

    1. Dhainaut J-F, Payet S, Vallet B, Riou-França L, Annane D, Bollaert P-E, Le Tulzo Y, Runge I, Malledant Y, Guidet B, et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care. 2007;11:R99. doi: 10.1186/cc6116. - DOI - PMC - PubMed
    1. Cox HL, Laupland KB, Manns BJ. Economic evaluation in critical care medicine. J Crit Care. 2006;21:117–124. doi: 10.1016/j.jcrc.2006.02.003. - DOI - PubMed
    1. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 2001;344:699–709. doi: 10.1056/NEJM200103083441001. - DOI - PubMed
    1. Angus DC, Linde-Zwirble WT, Clermont G, Ball DE, Basson BR, Ely EW, Laterre PF, Vincent JL, Bernard G, van Hout B. Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis. Crit Care Med. 2003;31:1–11. doi: 10.1097/00003246-200301000-00001. - DOI - PubMed
    1. Betancourt M, McKinnon PS, Massanari RM, Kanji S, Bach D, Devlin JW. An evaluation of the cost effectiveness of drotrecogin alfa (activated) relative to the number of organ system failures. Pharmacoeconomics. 2003;21:1331–1340. doi: 10.2165/00019053-200321180-00004. - DOI - PubMed